Entrada Therapeutics Inc (TRDA)
18.05
+0.12
(+0.67%)
USD |
NASDAQ |
Nov 21, 16:00
18.08
+0.02
(+0.14%)
After-Hours: 20:00
Entrada Therapeutics Enterprise Value: 226.09M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 226.09M |
| November 20, 2024 | 221.60M |
| November 19, 2024 | 215.61M |
| November 18, 2024 | 203.64M |
| November 15, 2024 | 218.60M |
| November 14, 2024 | 263.13M |
| November 13, 2024 | 297.56M |
| November 12, 2024 | 291.20M |
| November 11, 2024 | 294.94M |
| November 08, 2024 | 292.32M |
| November 07, 2024 | 270.24M |
| November 06, 2024 | 248.91M |
| November 05, 2024 | 247.42M |
| November 04, 2024 | 215.61M |
| November 01, 2024 | 209.25M |
| October 31, 2024 | 192.03M |
| October 30, 2024 | 195.07M |
| October 29, 2024 | 196.94M |
| October 28, 2024 | 200.30M |
| October 25, 2024 | 186.09M |
| October 24, 2024 | 180.48M |
| October 23, 2024 | 185.34M |
| October 22, 2024 | 191.33M |
| October 21, 2024 | 198.43M |
| October 18, 2024 | 202.92M |
| Date | Value |
|---|---|
| October 17, 2024 | 210.03M |
| October 16, 2024 | 211.15M |
| October 15, 2024 | 206.29M |
| October 14, 2024 | 217.51M |
| October 11, 2024 | 178.24M |
| October 10, 2024 | 141.96M |
| October 09, 2024 | 155.42M |
| October 08, 2024 | 163.65M |
| October 07, 2024 | 169.26M |
| October 04, 2024 | 189.08M |
| October 03, 2024 | 165.52M |
| October 02, 2024 | 159.91M |
| October 01, 2024 | 149.06M |
| September 30, 2024 | 148.32M |
| September 27, 2024 | 142.19M |
| September 26, 2024 | 116.89M |
| September 25, 2024 | 90.11M |
| September 24, 2024 | 103.13M |
| September 23, 2024 | 72.25M |
| September 20, 2024 | 76.34M |
| September 19, 2024 | 88.25M |
| September 18, 2024 | 38.03M |
| September 17, 2024 | 57.00M |
| September 16, 2024 | 71.51M |
| September 13, 2024 | 88.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-91.70M
Minimum
May 09 2022
971.53M
Maximum
Nov 17 2021
166.03M
Average
146.24M
Median
Aug 16 2023
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals Inc | 2.077B |
| Vertex Pharmaceuticals Inc | 109.46B |
| Assembly Biosciences Inc | -1.389M |
| Sarepta Therapeutics Inc | 10.58B |
| Regenxbio Inc | 199.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.03M |
| Revenue (Quarterly) | 19.57M |
| Total Expenses (Quarterly) | 41.23M |
| EPS Diluted (Quarterly) | -0.35 |
| Profit Margin (Quarterly) | -71.70% |
| Earnings Yield | 8.81% |
| Operating Earnings Yield | 8.87% |
| Normalized Earnings Yield | 8.809 |